Indeed, while several liquid biopsy panels, such as FoundationOne® Liquid CDx (Foundation Medicine, Inc., Cambridge, MA, USA), Guardant360® CDx (Guardant Health, Inc., Redwood City, CA, USA), PGDx elioTM Plasma Focus Dx (Personal Genome Diagnostics, Baltimore, MD, USA) and Shield® (Guardant Health, Inc., Redwood City, CA, USA), have been approved by the FDA for various solid tumors (e.g., lung, prostate and colorectal cancers), there are currently no clinically validated assays for ctDNA in MPNST or other NF1-associated tumors. Here, NF1 is linked to malignant peripheral nerve sheath tumor.